New drug applications approved by US FDA as of 01 - 15 August 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Treatment with metformin appears to significantly reduce tuberculosis (TB) risk in patients with type 2 diabetes mellitus, a study has found. However, this protective effect diminishes with age and is absent among those with metabolic disorders.
The use of the investigational first-in-class attachment inhibitor fostemsavir led to improved baseline viral and CD4+ T-cell counts in patients with HIV-1 infection who had limited treatment options and were failing their current antiretroviral regimen, according to the subgroup analysis results of the BRIGHTE* study presented at AIDS 2018.
Ageing, nondiabetic, HIV-positive individuals may have a greater tendency to develop insulin resistance than HIV-negative individuals, although their body mass index (BMI) and body fat levels were lower than that of HIV-negative individuals, a study from Thailand found.
Recurrence of Plasmodium vivax malaria following chloroquine treatment may be due to frequent under-dosing, according to a recent meta-analysis, which reports that add-on primaquine effectively prevents early recurrence.
Investigators from the University of Hong Kong (HKU) have discovered that a small molecule compound, M21, an inhibitor of C1pP, can attenuate the virulence of Staphylococcus aureus by suppressing the expression of multiple virulence factors.
Results of a study conducted by the Chinese University of Hong Kong (CUHK) revealed that patients who recovered from hepatitis B virus (HBV) infection are still at risk for hepatocellular carcinoma (HCC).
A US study suggests that expanding HIV screening to reduce undiagnosed infections and increasing access to care and treatment to achieve viral suppression are important to lessen HIV transmission. It is also imperative that prevention methods, such as condoms and pre-exposure prophylaxis, be easily accessed, particularly among young men who have sex with men (MSM) and MSM of colour.
In patients with chronic hepatitis B virus (HBV) infection, tenofovir alafenamide (TAF) shows comparable 96-week efficacy and improved renal and bone safety with tenofovir disoproxil fumarate (TDF), a recent study has shown.